Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NTP

This article was originally published in The Tan Sheet

Executive Summary

Bladderwrack, epigallocatechin-3-gallate (green tea extract polyphenol), grape seed and pine bark extracts accepted for carcinogenicity testing by program's Interagency Committee for Chemical Evaluation & Coordination, July 25 Federal Register notice states. National Cancer Institute nominated three ingredients, noting they have "significant exposure" to public through use in dietary supplements. ICCEC represents National Toxicology Program's first level of review; at May 25 meeting, program's Board of Scientific Counselors endorsed testing for SAM-e, black cohosh, blue-green algae, bilberry fruit extract, senna, yohimbe bark extract and hydergine (1"The Tan Sheet" June 4, p. 6)

You may also be interested in...



Supplement Composite Samples Best For NTP Study

The National Toxicology Program should use com-posite samples of products from multiple manufac-turers in its studies of dietary supplement ingredients, Clay Frederick, PhD, Rohm & Haas, suggested at the NTP Board of Scientific Counselors meeting in Research Triangle Park, N.C. May 25.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel